| Document |
Document Title |
|
WO/2018/218281A1 |
A process for inhibiting the formation of gas hydrates in a hydrocarbon fluid comprising adding to the hydrocarbon fluid, a gas hydrate anti-agglomerate which is a biodegradable anti-agglomerant derived from a naturally occurring substance.
|
|
WO/2018/221543A1 |
The present invention provides: an I-type crystal of (E)-2-(7-trifluoromethyl chromane-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaph
thalene-1-yl)acetamide having an excellent TRPV1 antagonistic activity; a medication and a medicat...
|
|
WO/2018/214639A1 |
Disclosed are a 2-azacyclo-5-trifluoromethyl-8-nitrobenzo(thio)pyran-4-one compound, a preparation method therefor and the use thereof in a drug for treating and/or preventing infectious diseases caused by Mycobacterium tuberculosis. In ...
|
|
WO/2018/212216A1 |
Provided is a method for producing an optically active isomer, the method including an asymmetry induction step in which an asymmetry-inducing agent is caused to act on chiral molecules having an enantiomeric-excess half-life period less...
|
|
WO/2018/209425A1 |
A solvent-free method to extract THCA from cannabis, said method comprising: providing a source of THCA-containing cannabis plant; providing a source of natural oil; combining said source of THCA-containing cannabis and said source of na...
|
|
WO/2018/205286A1 |
Provided is a conjugate containing a fluorescent chromophore, which has any structure selected from C1 to C3. The conjugate containing the fluorescent chromophore provided by the present invention comprises one fluorescent chromophore an...
|
|
WO/2018/205038A1 |
Pharmaceutical compositions comprising a mixture of cannabinoids and terpenes and use thereof in the treatment of select disorders mediated by the Hedgehog (HH) signaling pathway are disclosed. In preferred embodiments, the components of...
|
|
WO/2018/206096A1 |
The present invention relates to photochromic indeno fused phenanthrenopyran compounds represented by the following Formula (I). With some embodiments, the photochromic compounds represented by Formula (I) include at least one lengthenin...
|
|
WO/2018/205846A1 |
A method for extracting highly-effective natural plant anthocyanidin, which relates to the technical field of bioengineering. The method comprises the steps of: hydrolyzing anthocyanin; by using sodium bicarbonate or potassium bicarbonat...
|
|
WO/2018/199287A1 |
The present disclosure provides: a composition for treating and/or preventing crystalline retinopathy, the composition containing a cholesterol accumulation inhibitor; a method for treating and/or preventing crystalline retinopathy, the ...
|
|
WO/2018/194172A1 |
The present invention addresses the problem of providing a tricine derivative having higher antiviral activity. The compound according to the present invention is a compound represented by formula (I) or a salt thereof. (In formula (I), ...
|
|
WO/2018/190666A1 |
The present specification relates to a heterocyclic compound represented by chemical Formula 1, and an organic light-emitting element including same.
|
|
WO/2018/189210A1 |
The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these ...
|
|
WO/2018/191594A1 |
A method for treating a condition characterized by excessive adipose tissue in a subject, the method comprising administering to said subject a compound that inhibits adipogenesis and/or induces adipocyte apoptosis in said excessive adip...
|
|
WO/2018/186365A1 |
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...
|
|
WO/2018/183800A1 |
Disclosed are substituted (4'-hydroxylphenyl)cycloalkane compounds and substituted (4'-hydroxylphenyl)cycloalkene compounds and there use as selective agonists of the estrogen receptor beta isoform (ERβ). The disclosed compounds may be ...
|
|
WO/2018/183411A1 |
Compounds of formula (I) as inhibitors of DCNl and compositions containing the same are disclosed. Methods of using the DCNl inhibitors in the treatment of diseases and conditions wherein inhibition of DCNl provides a benefit, like oxida...
|
|
WO/2018/179998A1 |
The purpose of the present invention is to provide: a novel procyanidin having an excellent polysaccharide digestion inhibition effect; and a method for producing the same. Provided is a procyanidin characterized by having a basic skelet...
|
|
WO/2018/181683A1 |
The present invention addresses the problem of providing a novel polyimide which has a fluorene skeleton and which has low birefringence, and it was found that this problem can be solved by a polyimide which has a constituent unit derive...
|
|
WO/2018/175635A1 |
The present disclosure relates generally to herbicidal compositions and methods of use thereof, and more specifically to herbicidal compositions containing aspterric acid or a derivative thereof for use in inhibiting vegetative growth in...
|
|
WO/2018/174253A1 |
[Problem] To provide a fluorescent probe with which it is possible to selectively detect GSTP1 activity. [Solution] A nitrobenzene derivative represented by general formula (1) [in the formula, the symbols are defined as in the specifica...
|
|
WO/2018/168232A1 |
[Problem] A problem was presented in that conventional photochromic compounds cannot be considered adequate in terms of the coloring/decoloring rate and durability, and the production process therefor has many steps. The present inventio...
|
|
WO/2018/162651A1 |
The invention provides a compound of formula (I) wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; or a salt thereof; for use in the treatment and/or prophylaxis of a condition, disease or disorderin a sub...
|
|
WO/2018/162650A1 |
The invention provides a compound of formula (I) wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; or a salt thereof; for use in the treatment and/or prophylaxis of a condition, disease or disorderin a sub...
|
|
WO/2018/160022A1 |
The present disclosure relates to an organic electroluminescent device. The organic electroluminescent device of the present disclosure comprises a specific combination of a light-emitting layer and an electron transport zone, thereby pr...
|
|
WO/2018/159707A1 |
Provided is a method for purifying a substance, which includes: a step for preparing a solution that contains a solvent and one or more substances selected from a compound represented by formula (1A) and a resin having a structure repres...
|
|
WO/2018/159970A1 |
The present disclosure relates to an organic electroluminescent device comprising a light-emitting layer and a hole transport zone. By comprising a specific combination of a light-emitting layer and a hole transport zone, it is possible ...
|
|
WO/2018/152637A1 |
The current application relates to a method for forming a vaporizable liquid composition comprising a cannabinoid distillate from a plant product and 1,3 -propanediol as a mixing or cutting agent. The liquid composition is devoid of poly...
|
|
WO/2018/149857A1 |
The present invention relates to novel 2-oxo-2H-chromen compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositio...
|
|
WO/2018/148816A3 |
The invention describes extracts from plants of the genus Stachytarpheta enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders. The isolated active compounds and a process of producing these are ...
|
|
WO/2018/149855A1 |
The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic...
|
|
WO/2018/149850A1 |
The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic...
|
|
WO/2018/148816A2 |
The invention describes novel and inventive isolated compounds and the process of producing compounds and extracts with immunosuppressive activity, from plants of the genus Stachytarpheta. In this way, the present application also descri...
|
|
WO/2018/151261A1 |
[Problem] To provide a vitamin E production method and a vitamin E production device capable of increasing the purity of vitamin E in a vitamin E concentrate. [Solution] A raw material oil supply part 1 supplies a raw material oil to a s...
|
|
WO/2018/145213A1 |
Pharmaceutical compositions comprising cannabidiol (CBD), tetrahydrocannabinol (THC), and select omega-3 fatty acids are provided. The CBD and THC are present in a weight ratio of CBD:THC of 10:1 to 20:1. The omega-3 fatty acids comprise...
|
|
WO/2018/145342A1 |
Disclosed in the present invention is a method for preparing dihydrodaidzein, comprising the following steps: (1) using the compound represented by formula I as a raw material for an oxidation reaction to prepare a compound represented b...
|
|
WO/2018/148430A1 |
Methods and apparatuses for reducing the bioburden of cannabis using low-pressure radiant energy processing. The present invention achieves sufficient microbial killing and/or adequate drying without impacting product quality (terpene lo...
|
|
WO/2018/141263A1 |
A penicilones derivative and an application thereof as an anti-resistant bacteria drug, in particular relating to a compound of formula I, stereoisomers thereof, tautomers thereof, solvates thereof, prodrugs thereof, and pharmaceutically...
|
|
WO/2018/141050A1 |
The present invention relates to dosage forms for the production of flash-melt cannabis resin and extract oral dosage forms.
|
|
WO/2018/140738A1 |
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2) -related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as n...
|
|
WO/2018/132893A1 |
The present invention relates to immediate release pharmaceutical compositions comprising one or more natural or synthetic cannabinoids, and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to ...
|
|
WO/2018/135498A1 |
The present invention provides a compound represented by formula (O).
|
|
WO/2018/120971A1 |
Provided is a coumarin green light dye containing a triphenylamine ethylene side chain. The green light dye has a structure shown in formula (I), wherein R1, R2 and R3 independently represent hydrogen, a C1-C8 substituted or unsubstitute...
|
|
WO/2018/125880A1 |
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
|
|
WO/2018/115582A1 |
The invention relates to process for converting plant material to plant extract having antimicrobial activity, said process comprising the steps, where in the first step at least one plant material is ground in the presence of a first me...
|
|
WO/2018/116054A1 |
The present invention relates to new compounds deriving from spermatophyte plants belonging to the Hypericaceae family, in particular from Hypericum mexicanum having a fungicidal activity, and relative pharmaceutical compositions and use...
|
|
WO/2018/113201A1 |
A compound as represented by formula (I), or a stereoisomer, a tautomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof, a preparation method therefor, a pharmaceutical composition comprising ...
|
|
WO/2018/119263A1 |
Disclosed are compounds of Formula (I'), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing o...
|
|
WO/2018/118058A1 |
Method of isolating natural molecules: α and β pyranocycloartobiloxanthone A and Artonine E, from the stem bark of Artocarpus hirsutus and their anti-acne potential by inhibiting the growth of Propionibacterium acnes thereof, are descr...
|
|
WO/2018/107289A1 |
Compounds described herein are inhibitors of retinoic acid inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated c...
|
